EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
|
EQS-News: Heidelberg Pharma AG
/ Key word(s): Conference
PRESS RELEASE Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024 Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Heidelberg Pharma is an ADC specialist, developing innovative drugs based on its proprietary ADC toolbox for the targeted and highly effective treatment of cancer. Its lead Amanitin-based ADC product candidate, HDP-101, targeting relapsed or refractory multiple myeloma has recently received Orphan Drug Designation (ODD) and is currently advancing in a Phase I/IIa clinical trial, demonstrating first signs of clinical efficacy. The Company is also rapidly expanding its therapeutic product pipeline with a further four programs across a variety of malignant hematologic and solid tumors. 10th Annual Oncology Innovation Forum Presentation title: Company presentation Professor Pahl will be available for one-on-one meetings, which can be arranged via the online conference system. ASCO Annual Meeting Professor Pahl and Dr. Strassz will be available for meetings. BIO International Convention Dr. Badescu and Dr. Wischnjow will be available for one-on-one meetings, which can be arranged via the online conference system. Jefferies Global Healthcare Conference Professor Pahl and Dr. Badescu will be available for one-on-one meetings, which can be arranged via the online conference system.
Heidelberg Pharma develops novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma is the first company to use the mushroom toxin Amanitin in cancer therapy by exploiting the toxin's biological mechanism of action with its innovative ATAC technology as a new therapeutic modality. It offers the opportunity to overcome resistance of cancer cells against therapeutic agents currently used and to eliminate dormant tumor cells, which typically survive current therapies and are responsible for tumor relapse and metastasis. This could lead to significant advances in cancer therapy - even for patients who no longer respond to any other treatment. The most advanced product candidate HDP-101 is a BCMA-ATAC for the indication multiple myeloma, which is currently in clinical development. In addition to Amanitin, alternative payloads also expand the ADC platform technologies of Heidelberg Pharma to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com. ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will”, "should”, "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
23.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
||||
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Gregor-Mendel-Str. 22 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1909263 |
| End of News | EQS News Service |
|
|
1909263 23.05.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 7,31 | 8,49 | 1,75 | 18,51 | 9,86 | 6,85 | 8,20 | |
| EBITDA1,2 | -9,60 | -17,55 | -24,83 | -16,62 | -20,33 | -20,64 | 0,00 | |
| EBITDA-Margin3 | -131,33 | -206,71 | -1.418,86 | -89,79 | -206,19 | -301,31 | 0,00 | |
| EBIT1,4 | -10,14 | -18,28 | -25,63 | -17,18 | -21,21 | -20,67 | -30,00 | |
| EBIT-Margin5 | -138,71 | -215,31 | -1.464,57 | -92,82 | -215,11 | -301,75 | -365,85 | |
| Net Profit (Loss)1 | -10,15 | -18,37 | -26,14 | -19,70 | -20,35 | -19,38 | -32,00 | |
| Net-Margin6 | -138,85 | -216,37 | -1.493,71 | -106,43 | -206,39 | -282,92 | -390,24 | |
| Cashflow1,7 | -8,56 | -17,89 | -26,61 | -8,57 | -33,95 | -29,59 | 0,00 | |
| Earnings per share8 | -0,36 | -0,61 | -0,80 | -0,44 | -0,31 | -0,42 | -0,86 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Heidelberg Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A11QVV | DE000A11QVV0 | AG | 120,70 Mio € | 13.11.2006 | Kaufen | 8FXCFJCP+89 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -5,61 | 0,00 | 0,00 | -4,69 | 3,91 | -4,08 | 17,62 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.05.2025 | 24.04.2025 | 10.07.2025 | 09.10.2025 | 21.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -13,68% | -25,07% | +5,74% | +7,95% | -81,30% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
